All In Biotech

Drug Trial Radar · NCT06382948

Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.

A Randomized Phase 3, Double-Blind, Placebo-Controlled Study of Elacestrant Plus Everolimus Versus Elacestrant in Patients With ER+/HER2-, ESR1mut Advanced Breast Cancer Progressing to Endocrine Therapy and CDK4/6 Inhibitors

Last checked: Nov 19, 2026Latest source record: Aug 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Dec 5, 2024

Primary completion

Sep 2027

Study completion Apr 2028

Sponsor

Lead sponsor
MedSIRAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Stemline Therapeutics, Inc.
First posted
Apr 24, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial will study a type of advanced breast cancer (ABC) defined as endocrine receptor (ER)-positive/human epidermal growth factor receptor 2(HER2)-negative and estrogen receptor 1 (ESR1)-mutated. Patients will be treated with elacestrant, a compound that acts as a selective estrogen receptor degrader, and everolimus (or placebo), a kinase inhibitor indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer. The main purpose of the study is to analyze the efficacy (to find out how effective a treatment is) of elacestrant plus everolimus therapy in patients who have ER-positive/HER2-negative, ESR1-mutated, ABC progressing to endocrine therapy and cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. The efficacy of elacestrant plus everolimus combination will be determined by assessing the period from elacestrant plus everolimus (or placebo) treatment initiation until to the first occurrence of disease progression, unacceptable toxicity, death, or discontinuation from the study treatment for any other reason, whichever occurs first, defined as progression free survival. Rigorous eligibility criteria based on specific co-morbidities and clinicopathologic features of their disease have been designed to minimize the risk of patients participating in this study. The anticipated favorable clinical benefits of elacestrant combined with everolimus are projected to outweigh the risks of this treatment. This study will be performed in full compliance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) and all applicable local Good Clinical Practice (GCP) and regulations.

Conditions

  • Advanced Breast Cancer
  • ER-positive Breast Cancer
  • HER2-negative Breast Cancer
  • ESR1 Gene Mutation

Interventions

  • EverolimusDrug

    Patients will receive 7.5 mg of everolimus orally once daily.

  • ElacestrantDrug

    Patients will receive elacestrant 345 mg orally once daily

  • PlaceboDrug

    Patients will receive placebo orally once daily

  • Auxiliary Medicinal Product - DexamethasoneDrug

    10 mL of alcohol-free dexamethasone 0.5 mg per 5 mL mouthwashes (swish for 2 min and spit, four times daily for 8 weeks). After 8 weeks, dexamethasone mouthwash could be continued for up to eight additional weeks at the discretion of the clinician and patient. Used for prevention of treatment-induced stomatitis.

  • Auxiliary Medicinal Product - Luteinizing hormone-releasing hormone (LHRH) analoguesDrug

    According to clinical practice (for premenopausal/perimenopausal patients and male patients in both treatment arms). Used to suppress estrogen production.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To demonstrate superiority of elacestrant+everolimus vs. elacestrant+placebo in prolonging PFS based on a BIRC in patients with ER[+]/HER2[-], ESR1-mutated, ABC that have previously received ET+CDK4/6i (all patients).Time frame: Until disease progression, treatment discontinuation, the start of new anti-cancer treatment, withdrawal of consent, death, or EoS, whichever occurs first, assessed through study completion, an average of 12 months.

Locations

104 sites in 9 countries. Site status is shown where the registry gives one.

  • Medizinische Universität Innsbruck

    Innsbruck, Austria · Recruiting

  • Ordensklinikum Linz Barmherzige Schwestern

    Linz, Austria · Recruiting

  • Ordination Priv.-Doz. Dr. Michael Hubalek

    Schwaz, Austria · Recruiting

  • Medical University of Vienna

    Vienna, Austria · Not yet recruiting

  • Tacchini Instituto de Pesquisa

    Bento Gonçalves, Brazil · Not yet recruiting

  • Hospital Cachoeiro de Itapemirim

    Cachoeiro de Itapemirim, Brazil · Not yet recruiting

  • Catarina Pesquisa Clínica - Neoplasias Litoral

    Itajaí, Brazil · Not yet recruiting

  • UPCO - Hospital de Clinicas de Porto Alegre

    Porto Alegre, Brazil · Not yet recruiting

  • NOB Ondina

    Salvador, Brazil · Not yet recruiting

  • Masaryk Memorial Cancer Institute

    Brno, Czechia · Recruiting

  • Multiscan Nemocnice Horovice

    Hořovice, Czechia · Recruiting

  • University Hospital Olomouc

    Olomouc, Czechia · Not yet recruiting

  • General University Hospital Prague

    Prague, Czechia · Recruiting

  • Motol University Hospital

    Prague, Czechia · Recruiting

  • Tomas Bata Regional Hospital in Zlin

    Zlín, Czechia · Recruiting

  • Polyclinique Bordeaux Nord Aquitaine

    Bordeau, France · Recruiting

  • Institut Bergonié Bordeaux

    Bordeaux, France · Not yet recruiting

  • Centre Georges François Leclerc

    Dijon, France · Recruiting

  • Centre Hospitalier de Limoges

    Limoges, France · Recruiting

  • CHU Lyon Sud

    Lyon, France · Recruiting

  • Institut Paoli Calmettes

    Marseille, France · Not yet recruiting

  • APHP Tenon

    Paris, France · Not yet recruiting

  • Hospital prive des Cotes d'Amor

    Plérin, France · Recruiting

  • CHU Saint Etienne

    Saint-Priest-en-Jarez, France · Recruiting

  • Centre Paul Strauss

    Strasbourg, France · Recruiting

  • IUCT Oncopole

    Toulouse, France · Recruiting

  • Institute de Cancerologie de Lorraine - Nancy

    Vandœuvre-lès-Nancy, France · Recruiting

  • MVZ Klinikum Aschaffenburg

    Aschaffenburg, Germany · Not yet recruiting

  • Hämatologie-Onkologie im Zentrum MVZ GmbH

    Augsburg, Germany · Not yet recruiting

  • Städtisches Klinikum Dessau

    Dessau, Germany · Not yet recruiting

  • Universitätsklinikum Dusseldorf

    Düsseldorf, Germany · Not yet recruiting

  • Universitätsklinikum Essen

    Essen, Germany · Not yet recruiting

  • MVZ II der Niels Stensen Kliniken

    Georgsmarienhütte, Germany · Recruiting

  • Klinikum Worms - Frauenklinik

    Worms, Germany · Recruiting

  • University General Hospital Alexandroupoli

    Alexandroupoli, Greece · Recruiting

  • 251 Air Force General Hospital

    Athens, Greece · Recruiting

  • Aretaeio Hospital

    Athens, Greece · Recruiting

  • Attikon University Hospital

    Athens, Greece · Recruiting

  • Metropolitan General Hospital 4th department

    Athens, Greece · Recruiting

  • University General Hospital of Heraklion

    Heraklion, Greece · Recruiting

Showing 40 of 104 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.